Future perspective

Various studies and clinical trials have examined epigenetic therapies which shown the potential to decrease the burden of diseases in which abnormal epigenetic mechanisms play a critical role. Numerous therapeutic agents that can modulate epigenetic mechanisms in various disease conditions are under consideration for clinical use. Additional studies of the therapeutic approach to epigenetic therapy are required, as the procedure is not selective for target cells and activating gene expression in normal cells may make them cancerous. Further insight into the molecular mechanisms governing these epigenetic modulators will facilitate the design of more specific and effective drugs. The development of more specific HDAC inhibitors has shown great promise. Increasing target specificity will also significantly affect the development of more effective treatment options. The approval of two epigenetic drugs (Vidaza and romidepsin, HDAC inhibitors) by the US Food and Drug Administration has supported their use in disease treatment. Additionally, epigenetic profiling of patients may have predictive or prognostic value for epigenetic therapy. Thus, epigenetic biomarkers can be used to complement current strategies for diagnosis, prognosis, and prediction of drug responses and assist with therapeutic decision-making


    Related Conference of Future perspective

    November 29-30, 2021

    3rd International Conference on Neuroimaging and Neuroradiology

    Singapore, Singapore
    December 07-08, 2021

    2nd World Congres on Healthcare & Life-Science Research

    Bangkok, Thailand
    June 13-14, 2022

    4th World Congress on Complementary & Alternative Medicine

    Prague, Czech Republic

    Future perspective Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in